Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.

Naveen ReddyPramod ReddyAnkit RanpuraNarendra MaharajRajendersingh AroraGopichand MamillapalliAditya Shirish AdhavAshok Kumar DiwanAlexey ManikhasDmitriy Krasnozhon

Published in: JCO global oncology (2024)

DRL_TZ was found to have similar efficacy and comparable safety, PK, and immunogenicity profiles as the RMP.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
tyrosine kinase
advanced non small cell lung cancer
endothelial cells
induced pluripotent stem cells